Focinvez™ (fosaprepitant) – New drug approval
August 22, 2023 - The FDA approved Spes Pharmaceuticals’ Focinvez (fosaprepitant) injection, in combination with other antiemetic agents, in adults and pediatric patients 6 months of age and older for the prevention of:
- Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
- Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."
Top